FATE THERAPEUTICS INC
1.0700
16-May-25 13:45:00
15 minutes delayed
Stocks
+0.0600
+5.94%
Today's range
1.0000 - 1.1200
ISIN
N/A
Source
NASDAQ
-
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
15 Jul 2021 13:01:00 By Nasdaq GlobeNewswire
-
Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer
15 Jun 2021 05:00:01 By Nasdaq GlobeNewswire
-
04 Jun 2021 04:00:00 By Nasdaq GlobeNewswire
-
Fate Therapeutics to Present at Upcoming Investor Conferences
25 May 2021 13:01:00 By Nasdaq GlobeNewswire
-
13 May 2021 13:01:00 By Nasdaq GlobeNewswire
-
Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress
05 May 2021 13:01:00 By Nasdaq GlobeNewswire
-
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2021 Financial Results
29 Apr 2021 05:00:01 By Nasdaq GlobeNewswire
-
Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting
27 Apr 2021 13:31:00 By Nasdaq GlobeNewswire
-
Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service
25 Mar 2021 04:00:00 By Nasdaq GlobeNewswire
-
Fate Therapeutics to Present at Upcoming Investor Conferences
08 Mar 2021 04:00:00 By Nasdaq GlobeNewswire
-
Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress
24 Feb 2021 13:01:00 By Nasdaq GlobeNewswire
-
Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
22 Feb 2021 13:01:00 By Nasdaq GlobeNewswire
-
19 Feb 2021 05:00:00 By Nasdaq GlobeNewswire
-
08 Jan 2021 13:26:19 By Nasdaq GlobeNewswire
-
Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
05 Jan 2021 21:30:06 By Nasdaq GlobeNewswire
-
Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock
04 Jan 2021 13:01:00 By Nasdaq GlobeNewswire